MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$1,299K
Net Income
-$31,406K
Net Profit Margin
-2417.71%
EPS
-$0.26
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-03-31
Collaboration revenue
1,299 1,591* 1,741 1,629
Research and development
24,703 25,368* 25,838 29,136
General and administrative
9,596 9,905* 10,638 13,773
Impairment loss
NaN 0* NaN NaN
Total operating expenses
34,299 35,272* 36,476 42,909
Loss from operations
-33,000 -33,681* -34,735 -41,280
Interest income
1,867 2,186* 2,575 3,336
Change in fair value of stock price appreciation milestones
80 41* 90 -280
Other income
0 29* 0 43
Total other income
1,787 2,173* 2,485 3,659
Net loss
-31,213 -31,508* -32,250 -37,621
Unrealized loss on available-for-sale securities, net
-193 -173* 91 -77
Comprehensive loss
-31,406 -31,681 -32,159 -37,698
Basic EPS
-0.26 -0.266 -0.27 -0.32
Diluted EPS
-0.26 -0.266 -0.27 -0.32
Basic Average Shares
120,030,638 118,995,689 118,998,693 118,375,540
Diluted Average Shares
120,030,638 118,995,689 118,998,693 118,375,540
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$31,406K (16.69%↑ Y/Y)Interest income$1,867K (-44.03%↓ Y/Y)Net loss-$31,213K (17.03%↑ Y/Y)Unrealized loss onavailable-for-sale securities, net-$193K (-150.65%↓ Y/Y)Total other income$1,787K (-51.16%↓ Y/Y)Change in fair value ofstock price...$80K (128.57%↑ Y/Y)Loss from operations-$33,000K (20.06%↑ Y/Y)Collaboration revenue$1,299K (-20.26%↓ Y/Y)Total operatingexpenses$34,299K (-20.07%↓ Y/Y)Research and development$24,703K (-15.21%↓ Y/Y)General andadministrative$9,596K (-30.33%↓ Y/Y)

FATE THERAPEUTICS INC (FATE)

FATE THERAPEUTICS INC (FATE)